Second, the UK biobank does not include data on recognized markers of dementia pathology (measured using cerebrospinal fluid AD biomarkers, such as amyloid-β and tau, or PET imaging), and does not have results for global cognitive measures (including the Mini-Mental State Examination [MMSE] and the Montreal Cognitive Assessment [MOCA]). This evidence concerns the gene MAPT and Alzheimer disease.